Shekha A Alnajdi

Mrs. Shekha A Alnajdi

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2026 in The Canadian Journal of Psychiatry
Verified
Journal Article
Closed access
Abdullah M AlharranAbdullah M Alharran
Abdullah M Alharran
MAMariam M. Abdulraheem
Mariam M. Abdulraheem
BSBader Sabeq
Bader Sabeq
MAMohammad Alsowailem
Mohammad Alsowailem
KAKhaled Alsalem
Khaled Alsalem
AAAbdulrahman Hamad Aldousari
Abdulrahman Hamad Aldousari
Background: Depression in children and adolescents is a leading cause of disability worldwide, with rising prevalence and limited efficacy of conventional pharmacotherapies. Omega-3 polyunsaturated fatty acids (PUFAs) have emerged as a potential adjunctive or alternative treatment due to their anti-inflammatory and neuroprotective properties. However, evidence in paediatric populations remains inconclusive. This updated meta-analysis aims to evaluate the efficacy and safety of omega-3 PUFA supplementation versus placebo or standard care for depressive symptoms in children and adolescents. Methods: We conducted a systematic search for randomized controlled trials (RCTs) comparing omega-3 PUFA supplementation in children and adolescents with depressive disorders or clinically significant depressive symptoms. For the meta-analysis, we used R software (version 4.5.0) with the meta and metasens packages. Using a random-effects model, we evaluated continuous outcomes using standardized mean differences (SMDs) and dichotomous outcomes using risk ratios (RRs), each with 95 per cent confidence intervals (95% CIs). Trial sequential analysis (TSA) was performed to assess the robustness of findings and calculate required information sizes (RISs). Results: We included nine RCTs with a total of 848 participants. There were no statistically significant differences between omega-3 and control groups in change in depression symptom severity at any follow-up duration: 3–4 weeks, 6–8 weeks, 10–12 weeks, 16 weeks, or 24–26 weeks. Heterogeneity was significant across most subgroups, with I 2 ranging between 67.1 per cent and 91.8 per cent. Similarly, no significant effects were observed for response rate or remission rate at any time point, or all-cause dropouts. TSA indicated that the cumulative evidence did not reach the RIS. Conclusion: Omega-3 did not significantly improve depressive symptoms or remission in children and adolescents. However, TSA showed that the evidence remains underpowered, so a potential benefit cannot be excluded. Significant clinical heterogeneity and insufficient information size underscore the need for large-scale RCTs with standardized outcome measures.

Verified
Journal Article
Open access
PDF file
AAAbdulrahman Hamad Aldousari
Abdulrahman Hamad Aldousari
HAHamad Alkandari
Hamad Alkandari
SASulaiman Alruwaished
Sulaiman Alruwaished
YAYousef M. F. H. Almutairi
Yousef M. F. H. Almutairi
AAAbdulwahab Alkandari
Abdulwahab Alkandari
STSalah Termos
Salah Termos
Background: Laparoscopic cholecystectomy is the gold standard for gallbladder disease but is often associated with significant postoperative pain. Opioid analgesia is effective and is the mainstay of treatment. However, opioids are limited by multiple adverse effects such as nausea and respiratory depression. Esketamine is an NMDA receptor antagonist that has emerged as a potential analgesic adjunct. This systematic review and meta-analysis aims to evaluate the efficacy and safety of perioperative esketamine for patients undergoing laparoscopic cholecystectomy. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials comparing perioperative esketamine with control regimens in adults undergoing laparoscopic cholecystectomy. Five databases were searched from inception to 25 August 2025. Random-effects meta-analyses were performed for pain, hemodynamic, recovery, and safety outcomes. Results: Six randomized controlled trials including 569 patients were eligible. Esketamine was associated with lower pain scores at rest and during movement, although neither were statistically significant. No significant clinical differences were observed in mean arterial pressure or heart rate changes during surgery or after surgery. However, esketamine significantly shortened wake-up time (MD = −3.55 min, 95% CI [−6.09 to −1.02]), improved postoperative sleep quality (MD = −5.78, 95% CI [−6.80 to −4.76]), and reduced PONV (RR = 0.47, 95% CI [0.24 to 0.92]) and respiratory depression (RR = 0.18, 95% CI [0.03 to 0.98]). Conclusions: Esketamine improved selected recovery and safety outcomes but did not significantly reduce hemodynamic parameters, postoperative pain or rescue analgesia. Larger high-quality trials are needed to confirm its role in laparoscopic cholecystectomy.

19 May 2026 in The Canadian Journal of Psychiatry
Verified
Journal Article
Closed access
Abdullah M AlharranAbdullah M Alharran
Abdullah M Alharran
AAAbdulrahman Hamad Aldousari
Abdulrahman Hamad Aldousari
SAShekha A Alnajdi
Shekha A Alnajdi
LALayal T. Alwazzan
Layal T. Alwazzan
MAMunawer A. Alsaid
Munawer A. Alsaid
WAWaleed Bader Alazemi
Waleed Bader Alazemi
Background: Parents of children with autism spectrum disorder (ASD) experience significantly higher levels of stress, anxiety and depression. Acceptance and Commitment Therapy (ACT) has emerged as a promising intervention; however, the evidence remains inconsistent. This meta-analysis aims to evaluate the efficacy of ACT-based interventions in parents of children and adolescents with ASD. Methods: In February 2026, we conducted a systematic search of PubMed, Scopus, Web of Science, Cochrane Library and Embase for randomized controlled trials (RCTs) assessing ACT-based interventions in parents of children/adolescents with ASD. For the meta-analysis, we used R software (version 4.5.0) with RStudio (2024.12.1 + 563) and the meta package. Results: We included seven RCTs with a total of 698 participants. Acceptance and Commitment Therapy significantly reduced parenting stress compared to control conditions, as measured by the Parenting Stress Index – Short Form Total Stress (mean difference [MD] = −7.05, 95 per cent CI −9.90 to −4.19, p < 0.0001, I 2 = 0 per cent), with consistent improvements across all subscales (Parental Distress, Parent–Child Dysfunctional Interaction and Difficult Child). Acceptance and Commitment Therapy also significantly improved psychological flexibility on the Acceptance and Action Questionnaire-II and Parenting Sense of Competence scale. For child outcomes assessed in our analysis, ACT significantly reduced total difficulties on the Strengths and Difficulties Questionnaire (MD = −2.80, 95 per cent CI −4.71 to −0.88, P = 0.004, I 2 = 0 per cent) and conduct problems (MD = −0.98, 95 per cent CI −1.62 to −0.33, P = 0.003, I 2 = 0 per cent). Conclusion: Acceptance and Commitment Therapy-based interventions may be effective for reducing parenting stress, improving psychological flexibility, enhancing parenting competence and reducing child behavioural difficulties in parents of children with ASD. However, the limited number of studies and clinical heterogeneity might limit our findings, highlighting the need for future large-scale RCTs with longer follow-up.